Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals

August 17, 2026

Stanford Medicine USA

Overview

The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A recent breakthrough, oral semaglutide, demonstrates that sophisticated formulation techniques, including high peptide concentrations and absorption enhancers, can overcome these hurdles, paving the way for a new era in oral peptide drug delivery. This success story is catalyzing significant innovation in drug delivery systems.

In Depth

Background: The Promise and Challenge of Peptide Therapeutics

Peptides, molecules composed of two or more amino acids linked by peptide bonds, occupy a unique space between simple amino acids and complex proteins. Their distinct target-binding capabilities and favorable safety profiles have long positioned them as potent pharmaceutical agents. The pharmacological potential of peptides, recognized for their diverse physiological roles in vivo, has, however, been constrained by significant pharmacokinetic challenges. Oral administration, offering vast improvements in patient convenience and treatment adherence, has thus been a long-standing R&D holy grail for the pharmaceutical industry.

Key Findings: A Surge in Approvals and the Oral Delivery Conundrum

A recent comprehensive report from Stanford Medicine offers deep insights into the current landscape and future prospects of peptide therapeutics. The FDA has already approved nearly 100 peptide-based drugs, addressing a wide array of conditions from diabetes and multiple sclerosis to septic shock. Despite this surge in approvals, oral delivery of peptides remains a formidable challenge, with most approved peptide drugs administered via injection. However, the recent approval of oral semaglutide stands out as a remarkable success story, demonstrating a viable pathway to overcoming these long-standing barriers.

Technical and Clinical Details: Decoding Oral Semaglutide’s Success

The primary hurdles for oral peptide delivery stem from their inherent instability in the gastrointestinal (GI) tract’s acidic environment and susceptibility to proteolytic enzymes. Furthermore, their relatively large molecular size impedes efficient absorption across the intestinal epithelium. Consequently, ensuring sufficient bioavailability for most approved peptide therapeutics has necessitated parenteral administration, typically via subcutaneous or intravenous injection. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes and obesity, represents the singular, groundbreaking exception. Its formulation ingeniously incorporates a specialized absorption enhancer, sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), which mitigates degradation in the stomach and facilitates absorption in the small intestine. Crucially, the formulation also includes a significantly high concentration of the peptide to compensate for inevitable losses during digestion. This pioneering achievement unequivocally demonstrates that effective oral peptide delivery is attainable through advanced Drug Delivery Systems (DDS) technologies.

Industry Context and Broader Implications

The triumph of oral semaglutide has invigorated research in this domain, fueling expectations for novel technological advancements capable of enabling oral delivery for a wider range of peptides and protein-based therapeutics. Industry leaders like Lonza Capsugel, for instance, are actively exploring combinations of lipid-based formulations and enteric capsules to achieve oral delivery of GLP-1 peptides. Such advancements are pivotal for diversifying the administration routes of biopharmaceuticals and realizing a truly patient-centric healthcare paradigm.

Future Outlook: Pioneering New Delivery Avenues

The field of peptide therapeutics is poised for continuous expansion, driven by relentless innovation in DDS technologies. Oral semaglutide’s success serves as a crucial benchmark, galvanizing the development of numerous other oral peptide therapies. Researchers are now intensely focused on several key areas: chemical modifications to enhance peptide stability, novel excipients and sophisticated delivery systems (such as nanoparticles, microcapsules, and transdermal patches) to boost gastrointestinal absorption, and AI-driven optimization of formulation design. These concerted efforts promise a future where many peptide therapeutics, historically confined to injectables, will become available as convenient oral formulations. This paradigm shift holds the potential to fundamentally transform the treatment landscape for a variety of chronic conditions, including diabetes, obesity, and osteoporosis, ushering in an era of more accessible and patient-friendly therapies.

Source: https://med.stanford.edu/news/insights/2026/08/peptides-what-does-the-science-say.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.